title: Proarrhythmic effects of a quinidine analog in dogs with chronic A-V block.
abstract: The proarrhythmic effects of 3-hydroxy-hydroquinidine (3-OH-HQ) and quinidine were compared in a canine model of QT-dependent ventricular arrhythmias. Eight hypokalemic ([K+] < or = 3.2 mmol/l) dogs with AV block (around 45 bpm) were given either drug in a randomized order at 2-day intervals. Each drug was given as two 1 hour doses, with a bolus (low dose: 5 mg/kg or high dose: 10 mg/kg) plus infusion (25 or 50 micrograms/kg/min) protocol. Propranolol infusion was combined with a third hour of the high dose infusion. Electrophysiologic measurements were performed at baseline and 30 minutes after the beginning of each dose and propranolol infusion, and proarrhythmic events were recorded 30 minutes before and during the experiment. Neither drugs altered the ventricular cycle length. Quinidine and 3-OH-HQ prolonged the QT interval similarly and significantly when paced at 60 bpm after the low dose (+39 +/- 18 and +28 +/- 22 msec, respectively) and after the high dose (+51 +/- 29 and +50 +/- 22 msec). Quinidine was more arrhythmogenic than 3-OH-HQ: 7/8 dogs (p < or = 0.05) developed ventricular arrhythmias (isolated, repetitive ventricular beats, or polymorphic ventricular tachycardias) during quinidine infusion (low dose: 4 dogs) compared to 3/8 dogs (NS) during 3-OH-HQ infusion (low dose: 1 dog). Addition of propranolol-induced bradycardia (around 30 bpm) caused torsades de pointes (wave burst arrhythmias) or polymorphic ventricular tachycardias after both drugs (in 3 dogs after quinidine and in 2 dogs after 3-OH-HQ). Thus 3-OH-HQ was slightly less arrhythmogenic than quinidine in this model of torsades de pointes, but the addition of an extra favouring factor (bradycardia) reduced that difference.
authors.affiliation: Laboratoire de Pharmacologie, Faculté de Médecine Saint-Antoine, Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Chézalviel-Guilbert
authors.forename: J
authors.initials: J
authors.lastname: Weissenburger
authors.forename: J M
authors.initials: JM
authors.lastname: Davy
authors.forename: C
authors.initials: C
authors.lastname: Guhennec
authors.forename: J M
authors.initials: JM
authors.lastname: Poirier
authors.forename: G
authors.initials: G
authors.lastname: Cheymol
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000139:chemically induced* / Q000503:physiopathology; D005117:Cardiac Complexes, Premature / Q000139:chemically induced / Q000503:physiopathology; D004285:Dogs; D004562:Electrocardiography / Q000187:drug effects; D004594:Electrophysiology; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D011433:Propranolol / Q000494:pharmacology; D011802:Quinidine / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000633:toxicity; D017180:Tachycardia, Ventricular / Q000503:physiopathology
chemical_list: D000319:Adrenergic beta-Antagonists; C039166:3-hydroxyhydroquinidine; D011433:Propranolol; D011802:Quinidine